Caixin
Jan 06, 2023 09:14 PM
CHINA

Analysis: China’s Limits on Dispensing Pfizer’s Paxlovid Could Delay Treatment

Pfizer’s antiviral Covid pill Paxlovid. Photo: VCG
Pfizer’s antiviral Covid pill Paxlovid. Photo: VCG

As China’s local health centers stock up on more of the highly sought-after Covid pill, Pfizer Inc.’s antiviral Paxlovid, the still limited supply has prompted some clinics to impose strict restrictions on buyers, raising concerns that those in urgent need could face delays.

In late December, Beijing city authorities began distributing the Covid pill to local community health centers, followed by Shanghai and Guangzhou. The move comes as Covid rages across the country, prompting calls to increase the supply of different antiviral drugs to keep up with soaring demand.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST